Funding Opportunity RFA-AA-20-002 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on alcohol use disorder and the impact of alcohol on health and disease. The NIAAA Centers Program provides leadership in research, research methodology development and information dissemination on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to, investigations into the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan. Where applicable and of significant health concern, comorbidity can be included. Centers are also major contributors to the development of new research methods, technologies, and approaches that sustain innovative goal-directed research.

Notice NOT-DA-19-037 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-20-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

Funding Opportunity RFA-DA-20-007 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

Notice NOT-OD-19-109 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-048 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-708 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-038 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-121 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-114 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-19-011 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDGs Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins. The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base.

Funding Opportunity RFA-HD-20-015 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

Funding Opportunity RFA-DA-20-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.

Funding Opportunity PAR-19-315 from the NIH Guide for Grants and Contracts. The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Funding Opportunity PAR-19-313 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) invites applications for Centers of Biomedical Research Excellence (COBRE) from investigators at Universities that award doctoral degrees in the health-related sciences or independent biomedical research institutes/medical centers with ongoing biomedical research programs funded by NIH or other federal agencies within Institutional Development Award (IDeA)-eligible states. The objectives of the COBRE initiative are to strengthen an institution's biomedical research infrastructure through the establishment of a thematic multi-disciplinary center and to enhance the ability of investigators to compete independently for NIH individual research grants or other external peer-reviewed support. COBRE awards are supported through the IDeA Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH.

Funding Opportunity PAR-19-312 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for NIH individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH. The goal of this FOA is to support existing COBRE Phase 1 Centers by further strengthening the research infrastructure and to continue the development and support of a critical mass of investigators with the expertise in the Center's scientific interest areas.

Funding Opportunity PAR-19-311 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660).

Notice NOT-GM-19-047 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-20-004 from the NIH Guide for Grants and Contracts. The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimers disease (AD) and AD-related dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.

Notice NOT-OD-19-115 from the NIH Guide for Grants and Contracts